MUNICH--(BUSINESS WIRE)--CatalYm today announced three major expansions of its ongoing Phase 2 visugromab clinical development program. Based on initial positive patient responses, the company is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback